Patents by Inventor Jacob Lee Houghton

Jacob Lee Houghton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220040337
    Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.
    Type: Application
    Filed: September 1, 2021
    Publication date: February 10, 2022
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Brian ZEGLIS, Jason LEWIS, Thomas REINER, Jacob Lee HOUGHTON, Jan-Philip MEYER, Christian BRAND
  • Patent number: 11135320
    Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: October 5, 2021
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Brian Zeglis, Jason Lewis, Thomas Reiner, Jacob Lee Houghton, Jan-Philip Meyer, Christian Brand
  • Publication number: 20190091351
    Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.
    Type: Application
    Filed: November 28, 2018
    Publication date: March 28, 2019
    Applicant: Memorial Sloan Kettering Cancer Center
    Inventors: Brian ZEGLIS, Jason LEWIS, Thomas REINER, Jacob Lee HOUGHTON, Jan-Philip MEYER, Christian BRAND
  • Publication number: 20160331852
    Abstract: Described herein are Tz/TCO-based pretargeting strategies using an Al[18F]-NOTA-labeled tetrazine radioligand. This imaging strategy enables delineation of cancer at earlier time points compared to other imaging strategies and further decreases the radiation dose to healthy tissues compared to directly labeled antibodies. Al-based 18F imaging of small molecules, such as tetrazine, has not been previously achieved due to the decomposition of tetrazine during radiofluorination. Radiofluorination is advantageous over other radiolabeling methods because, in addition to having a shorter half-life, 18F is more readily available to produce and therefore integrated into hospital workflows.
    Type: Application
    Filed: August 14, 2015
    Publication date: November 17, 2016
    Inventors: Brian Zeglis, Jason Lewis, Thomas Reiner, Jacob Lee Houghton, Jan-Philip Meyer